441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Ovid's OV329 Shows Strong Inhibitory Activity & Best-in-Category Safety
Other Events
Reports Business Updates and Second Quarter 2025 Financial Results
Shareholder votes
Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Annual Report to Security Holders
Reports Business Updates and First Quarter 2025 Financial Results
Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
PREM14A
Correspondence
Submission Upload
S-8 POS